ABSTRACT
BCR-ABL kinase domain (KD) mutations are well known for causing resistance against tyrosine kinase inhibitors (TKIs) and disease progression in chronic myeloid leukemia (CML). In recent years, compound BCR-ABL mutations have emerged as a new threat to CML patients by causing higher degrees of resistance involving multiple TKIs, including ponatinib. However, there are limited reports about association of compound BCR-ABL mutations with disease progression in imatinib (IM) sensitive CML patients. Therefore, we investigated presence of ABL-KD mutations in chronic phase (n = 41), late chronic phase (n = 33) and accelerated phase (n = 16) imatinib responders. Direct sequencing analysis was used for this purpose. Eleven patients (12.22%) in late-CP CML were detected having total 24 types of point mutations, out of which 8 (72.72%) harbored compound mutated sites. SH2 contact site mutations were dominant in our study cohort, with E355G (3.33%) being the most prevalent. Five patients (45%) all having compound mutated sites, progressed to advanced phases of disease during follow up studies. Two novel silent mutations G208G and E292E/E were detected in combination with other mutants, indicating limited tolerance for BCR-ABL1 kinase domain for missense mutations. However, no patient in early CP of disease manifested mutated ABL-KD. Occurrence of mutations was found associated with elevated platelet count (p = 0.037) and patients of male sex (p = 0.049). The median overall survival and event free survival of CML patients (n = 90) was 6.98 and 5.8 y respectively. The compound missense mutations in BCR-ABL kinase domain responsible to elicit disease progression, drug resistance or disease relapse in CML, can be present in yet Imatinib sensitive patients. Disease progression observed here, emphasizes the need of ABL-KD mutation screening in late chronic phase CML patients for improved clinical management of disease.
Subject(s)
Antineoplastic Agents/pharmacology , Drug Resistance, Neoplasm/genetics , Fusion Proteins, bcr-abl/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Neoplasm Recurrence, Local/genetics , Protein Kinase Inhibitors/pharmacology , Adolescent , Adult , Antineoplastic Agents/therapeutic use , Child , DNA Mutational Analysis , Disease Progression , Disease-Free Survival , Female , Follow-Up Studies , Humans , Imatinib Mesylate/therapeutic use , Kaplan-Meier Estimate , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality , Male , Middle Aged , Mutation, Missense , Neoplasm Recurrence, Local/blood , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/mortality , Platelet Count , Point Mutation , Protein Kinase Inhibitors/therapeutic use , Young AdultABSTRACT
Cupriavidus metallidurans CH34 and Pseudomonas putida mt2 were used as cadmium (Cd)-resistant and -sensitive bacteria, respectively, to study Cd uptake, sorption, intracellular accumulation, metallothionein (MT) induction, and bioremediation potential of both isolates. According to this research work, Cd had a stimulatory effect on the growth of CH34 cells (OD578 = 1.43) compared with mt2 cells (OD578 = 0.8). Addition of N,N'-dicyclohexylcarbodiimide (DCCD) and 2,4-dinitrophenol (DNP) along with Cd resulted in more cell growth in mt2 (OD578 = 0.71) compared with CH34 (OD578 = 0.34). DCCD and DNP inhibited this active uptake only in CH34 but not in mt2. Greater Cd interaction with the cell surface was observed in mt2 cells compared with CH34 cells. Intracellular Cd accumulation was interrupted by DCCD and DNP in CH34 (only 1.81 ± 0.04 µg L(-1) at 5 h) but not in mt2 (24.41 ± 0.01 µg L(-1) at 5 h). Intracellular Cd uptake was observed in even killed mt2 cells (7.11 ± 0.05 µg L(-1) at 5 h) compared with CH34 cells (2.50 ± 0.08 µg L(-1) at 5 h). This result showed that the Cd accumulation mechanism in CH34 is ATPase-dependent, whereas in mt2 uptake mechanism is not ATPase-dependent because mt2 ATPase was not inhibited by DCCD and DNP. CH34 removed 93 mg L(-1) of Cd after 8 days from original industrial effluent, which was more than Cd removal by CH34 from distilled water (i.e. 90 mg L(-1) after 8 days). mt2 was able to remove 80 mg L(-1) of Cd after 8 days from original industrial effluent, which was more than Cd removal by mt2 from distilled water (i.e. 77 mg L(-1) after 8 days). Cd did not induce any MT in CH34, but it did so in mt2 (14 kDa), which was thought to be a Cd-resistance mechanism operative in mt2.
Subject(s)
Cadmium/toxicity , Cupriavidus/physiology , Environmental Pollutants/toxicity , Pseudomonas putida/physiology , Adaptation, Physiological , Adenosine Triphosphatases/metabolism , Biodegradation, Environmental , Cadmium/metabolism , Environmental Pollutants/metabolism , Metallothionein/metabolismABSTRACT
To use of microorganisms for bioremediation purposes, the study of their motility behavior toward metals is essential. In the present study, Cupriavidus metallidurans CH34 and Pseudomonas putida mt2 were used as cadmium (Cd)-resistant and -sensitive bacteria, respectively, to evaluate the effects of Cd on their motility behaviors. Potassium morpholinopropane sulfonate (MOPS) buffer was used to observe the motility behavior of both isolates. Movement of mt2 was less in MOPS buffer compared with CH34, likely reflecting the mono-flagellated nature of mt2 and the peritrichous nature of CH34. The swimming, swarming, twitching, and chemotaxis behaviors of mt2 were greater in the presence of glucose than that of Cd. mt2 exhibited negative motility behaviors when exposed to Cd, but the opposite effect was seen in CH34. Cd was found to be a chemorepellent for mt2 but a chemoattractant for CH34, suggesting that CH34 is a potential candidate for metal (Cd) bioremediation.
